MTVA (MetaVia) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MTVA MetaVia Inc MTVA
30 GF Score
Price $1.42
! 1 Warning Sign
View Full Analysis

What is MetaVia FFO?

FFO (Funds from operations) only applies to REITs.

MTVA
30GF Score
MetaVia Inc MTVA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MetaVia Business Description

Address 545 Concord Avenue, Suite 210, Cambridge, MA, USA, 02138
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
30GF Score

Get the complete analysis for MTVA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.42
Price